Tumor-targeted chemotherapy could potentially eradicate cancers if anticancer drugs are delivered precisely to the cancers. We developed a tumor-targeting nanomedicine platform, in which drug is encapsulated with the ideal nanocarrier, human serum albumin complex. It allows the formulation of anticancer drug without toxic organic solvents. Moreover, it preferentially delivers toxic drugs to the tumor tissue, not to the normal tissues. Using this platform, the tumor-targeting nanomedicine of paclitaxel is now in the clinical trial stage.
Targeting-enhanced anticancer nanoparticles and preparation methods the same.